GHRH Receptor Drives Eye Inflammation Through JAK2/STAT3 — Blocking It Reduces Uveitis
The GHRH receptor activates a JAK2/STAT3 inflammatory cascade in eye tissue, and blocking this pathway with a GHRH antagonist or JAK inhibitor reduced acute uveitis in rats.
Quick Facts
What This Study Found
GHRH-R specifically activates JAK2/STAT3 signaling in ocular inflammation; both the GHRH-R antagonist MIA-602 and JAK inhibitor ruxolitinib reduced acute uveitis.
Key Numbers
GHRH-R → JAK2 → STAT3 → IL-6/IL-17A/COX2/iNOS; MIA-602 suppressed STAT3; ruxolitinib partially alleviated uveitis in vivo
How They Did This
Multi-model approach: human ciliary epithelial cells, rat iris/ciliary body explants, and in vivo rat endotoxin-induced uveitis. Methods included co-immunoprecipitation, bioinformatics, phosphorylation assays, and inflammatory marker quantification.
Why This Research Matters
Uveitis is a leading cause of blindness with limited treatment options. Identifying GHRH-R as a druggable inflammatory mediator in the eye opens new therapeutic avenues.
The Bigger Picture
GHRH-R antagonists are being developed for cancer. This study reveals an unexpected application in eye inflammation, potentially expanding the clinical utility of this drug class.
What This Study Doesn't Tell Us
Rat model of endotoxin-induced uveitis may not fully represent autoimmune uveitis in humans; ruxolitinib only partially alleviated inflammation; MIA-602 not tested in vivo in this study.
Questions This Raises
- ?Would topical eye drops containing GHRH-R antagonists be effective for uveitis?
- ?Is the GHRH-R/JAK2/STAT3 axis also active in chronic/autoimmune uveitis?
- ?Could existing JAK inhibitors already in use for rheumatoid arthritis be repurposed for uveitis?
Trust & Context
- Key Stat:
- JAK2-specific GHRH-R directly interacts with JAK2 (not JAK1, JAK3, or TYK2) to drive ocular inflammation
- Evidence Grade:
- Moderate — comprehensive multi-model mechanistic study with human cell validation, but partial efficacy in vivo.
- Study Age:
- Published in 2020; JAK inhibitors for eye disease have gained interest since.
- Original Title:
- Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.
- Published In:
- Proceedings of the National Academy of Sciences of the United States of America, 117(11), 6067-6074 (2020)
- Authors:
- Liang, Wei Cheng, Ren, Jia Lin, Yu, Qiu Xiao, Li, Jian, Ng, Tsz Kin, Chu, Wai Kit, Qin, Yong Jie, Chu, Kai On, Schally, Andrew V, Pang, Chi Pui, Chan, Sun On
- Database ID:
- RPEP-04954
Evidence Hierarchy
Frequently Asked Questions
What is uveitis?
Inflammation of the uvea (middle layer of the eye), which can cause pain, redness, and vision loss. It's one of the leading causes of preventable blindness.
How does a growth hormone receptor cause eye inflammation?
The GHRH receptor isn't just in the pituitary — it's also in eye tissue. When activated by inflammation, it turns on the JAK2/STAT3 pathway that produces inflammatory chemicals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04954APA
Liang, Wei Cheng; Ren, Jia Lin; Yu, Qiu Xiao; Li, Jian; Ng, Tsz Kin; Chu, Wai Kit; Qin, Yong Jie; Chu, Kai On; Schally, Andrew V; Pang, Chi Pui; Chan, Sun On. (2020). Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.. Proceedings of the National Academy of Sciences of the United States of America, 117(11), 6067-6074. https://doi.org/10.1073/pnas.1904532117
MLA
Liang, Wei Cheng, et al. "Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.." Proceedings of the National Academy of Sciences of the United States of America, 2020. https://doi.org/10.1073/pnas.1904532117
RethinkPeptides
RethinkPeptides Research Database. "Signaling mechanisms of growth hormone-releasing hormone rec..." RPEP-04954. Retrieved from https://rethinkpeptides.com/research/liang-2020-signaling-mechanisms-of-growth
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.